Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

3.

Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.

Rocha R, Nunes C, Rocha G, Oliveira F, Sanches F, Gobbi H.

Pathol Res Pract. 2008;204(9):655-62. doi: 10.1016/j.prp.2008.03.010. Epub 2008 Jun 18.

PMID:
18565685
5.
6.

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.

Regitnig P, Reiner A, Dinges HP, Höfler G, Müller-Holzner E, Lax SF, Obrist P, Rudas M, Quehenberger F.

Virchows Arch. 2002 Oct;441(4):328-34. Epub 2002 Sep 17.

PMID:
12404057
7.
8.

Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.

Oluwasola AO, Malaka D, Khramtsov AI, Ikpatt OF, Odetunde A, Adeyanju OO, Sveen WE, Falusi AG, Huo D, Olopade OI.

Ann Diagn Pathol. 2013 Dec;17(6):526-30. doi: 10.1016/j.anndiagpath.2013.07.003. Epub 2013 Oct 2.

9.
10.

The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.

Rhodes A, Sarson J, Assam EE, Dean SJ, Cribb EC, Parker A.

Am J Clin Pathol. 2010 Oct;134(4):621-32. doi: 10.1309/AJCPOG3O3KTPZQNK.

PMID:
20855644
11.

Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.

Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN.

Arch Pathol Lab Med. 2010 Jun;134(6):930-5. doi: 10.1043/1543-2165-134.6.930.

PMID:
20524870
12.

Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.

Rocha RM, Nunes CB, Sanches FS, Rocha GF, Oliveira FN, Reis-Filho JS, Lambros MB, Gobbi H.

Rev Assoc Med Bras (1992). 2009 Mar-Apr;55(2):163-8.

13.

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

PMID:
17536315
14.

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.

Reiner-Concin A, Regitnig P, Dinges HP, Höfler G, Lax S, Müller-Holzner E, Obrist P, Rudas M.

Pathol Oncol Res. 2008 Sep;14(3):253-9. doi: 10.1007/s12253-008-9079-z. Epub 2008 Aug 28.

PMID:
18752057
15.

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.

Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Magee H, Barnett S, Miller K.

J Clin Pathol. 2007 Jul;60(7):816-9. Epub 2006 Sep 8.

16.

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ.

Mod Pathol. 2007 May;20(5):584-91. Epub 2007 Mar 30.

18.

Comparison of different antibodies for detection of progesterone receptor in breast cancer.

Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP.

Steroids. 2002 Aug;67(9):799-813.

PMID:
12123792
20.

Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.

Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, Spina D, Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.

Anal Quant Cytol Histol. 2006 Apr;28(2):97-103.

PMID:
16637512

Supplemental Content

Support Center